Amylin Pharma (AMLN) Posts Wider than Expected Q2 Loss; Revs Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts AMLN Hot Sheet
Price: $30.98 --0%
Financial Fact:
Collaborative profit sharing: 0
Today's EPS Names:
OPY, BNCC, ZVOI, More
Financial Fact:
Collaborative profit sharing: 0
Today's EPS Names:
OPY, BNCC, ZVOI, More
Join SI Premium – FREE
Amylin Pharma (NASDAQ: AMLN) reported Q2 loss of ($0.21), $0.03 worse than the analyst estimate of ($0.18). Revenue for the quarter came in at $158.07 million versus the consensus estimate of $157.72 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Verra Mobility (VRRM) Tops Q3 EPS by 10c ; Offers Guidance
- Dominion Energy (D) Tops Q3 EPS by 9c, Beats on Revenue; Offers FY26 EPS Guidance
- nVent Electric (NVT) Tops Q3 EPS by 13c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
